Additionally, a recent study showed that the CDK4/6 inhibitor palbociclib can effectively improve the radiosensitivity of ESCC cells in vivo and in vitro by suppressing mTOR and thus has great potential to act as a radiosensitization agent for ESCC treatment 148(Table 3). Here, CDK4 is linked to esophageal squamous cell carcinoma.